THE ORAL THIN FILM EDGE:

5 STRATEGIC ADVANTAGES PHARMA LEADERS OF THE FUTURE ARE BANKING ON

When a branded therapy loses exclusivity, generics capture over 90% of prescriptions within months. Oral thin films offer a strategic path forward, extending product life by 3-7 years, improving bioavailability by up to 200%, and simplifying administration.

Download the guide to see how leading pharma companies are using OTF platforms to protect market share and build stronger pipelines.

DOWNLOAD THE GUIDE

How formulation and manufacturing process patents extend market exclusivity 3-7 years beyond API expiration, creating barriers to generic entry.

Patent extension strategies

A STRATEGIC RESOURE FOR PHARMACEUTICAL AND BIOTECH DECISION-MAKERS

The Oral Thin Film Edge explores how leading companies use oral thin film (OTF) platforms to defend market share, enhance therapeutic performance, and reach patient populations that conventional tablets can’t serve. Drawing on ARx’s experience supporting four FDA approvals and producing over 100 million units annually, this guide offers practical frameworks for assessing feasibility, regulatory pathways, and development timelines.

Inside, you’ll discover:

SEE WHERE ORAL THIN FILMS FIT IN YOUR DEVELOPMENT STRATEGY

Acting now helps your team de-risk development and build a stronger, more competitive pipeline, positioning your therapies for lasting impact.

Bioavailability optimization

Accelerated development timelines

Platform selection frameworks

Real-world development processes

How the 505(b)(2) regulatory pathway compresses traditional development from 6-8 years to 24-36 months.

Why sublingual and buccal delivery achieve 40–200% improvements in systemic exposure versus oral tablets, enabling lower doses and better safety profiles.